Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Segment Definitions
1.2.1. Test
1.2.2. Application
1.2.3. End Use
1.2.4. Estimates and forecasts timeline
1.3. Objectives
1.3.1. Objective-1
1.3.2. Objective-2
1.3.3. Objective-3
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased database
1.5.2. internal database
1.5.3. Secondary sources
1.5.4. Primary research
1.6. Information or Data Analysis
1.6.1. Data analysis models
1.7. Market Formulation & Validation
1.8. Model Details
1.8.1. Commodity flow analysis
1.8.1.1. Approach 1: Commodity flow approach
1.8.1.2. Approach 2: Country-wise market estimation using bottom-up approach
1.9. List of Secondary Sources
1.10. List of Primary Sources
1.11. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Test Snapshot
2.3. Application and End-use Snapshot
2.4. Competitive Insights
Chapter 3. U.S. Latent Tuberculosis Infection Detection Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook (Latent Tuberculosis Infection Detection Market)
3.1.2. Related/ancillary market outlook (Tuberculosis Diagnostics Market)
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Increase in risk of developing active Tuberculosis Infection from LTBI
3.2.1.2. Increasing Funding Programs to Promote TB Diagnostics
3.2.1.3. Technological Advancements in Diagnostics Methods
3.2.2. Market Restraint Analysis
3.2.2.1. Limited Awareness and Underdiagnosis of Latent TB
3.2.3. Market Opportunity Analysis
3.2.3.1. Growing Focus on TB Elimination and Preventive Care
3.2.3.2. Expansion of Community-Based and Targeted Screening Programs
3.2.4. Market Challenge Analysis
3.2.4.1. Low Disease Visibility and Competing Public Health Priorities
3.3. U.S. Latent Tuberculosis Infection Detection Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Bargaining power of suppliers
3.3.1.2. Bargaining power of buyers
3.3.1.3. Threat of substitutes
3.3.1.4. Threat of new entrants
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Economic landscape
3.3.2.3. Social landscape
3.3.2.4. Technological landscape
3.3.2.5. Environmental landscape
3.3.2.6. Legal landscape
3.4. Regulatory Framework
3.5. Reimbursement Scenario
3.6. Payment/ Reimbursement for Immigration Testing
3.7. CLIA Labs in the U.S.
3.7.1. List of all the CLIA Labs in the U.S
3.7.2. List of CLIA and NYS Certified Labs that Perform QFT (CPT 86480), T-SPOT.TB (86481), TST (86580), and their Volumes
3.7.3. List of Physicians and Volumes Ordered of the Tests Split out by NPI, Geography, and Practice
Chapter 4. U.S. Latent Tuberculosis Infection Detection Market: Test Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. U.S. Latent Tuberculosis Infection Detection Market: Test Movement Analysis
4.3. U.S. Latent Tuberculosis Infection Detection Market by Test Outlook (USD Million)
4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033, for the following
4.5. Interferon Gamma Released Assay (IGRA)
4.5.1. Interferon Gamma Released Assay (IGRA) Market Revenue Estimates and Forecasts, 2021-2033 (USD Million)
4.5.2. Interferon Gamma Released Assay (IGRA) Market Estimates and Forecasts, 2021-2033 (Number of Tests, in Thousands)
4.5.3. QFT
4.5.3.1. QFT Market Revenue Estimates and Forecasts, 2021-2033 (USD Million)
4.5.3.2. QFT Market Revenue Estimates and Forecasts, 2021-2033 (Number of Tests, in Thousands)
4.5.4. T. SPOT
4.5.4.1. T. SPOT Market Revenue Estimates and Forecasts, 2021-2033 (USD Million)
4.5.4.2. T. SPOT Market Revenue Estimates and Forecasts, 2021-2033 (Number of Tests, in Thousands)
4.6. Tuberculin Skin Test (TST)
4.6.1. Tuberculin Skin Test (TST) Market Revenue Estimates and Forecasts, 2021-2033 (USD Million)
4.6.2. Tuberculin Skin Test (TST) Market Revenue Estimates and Forecasts, 2021-2033 (Number of Tests, in Thousands)
Chapter 5. U.S. Latent Tuberculosis Infection Detection Market: Application Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. U.S. Latent Tuberculosis Infection Detection Market: Application Movement Analysis
5.3. U.S. Latent Tuberculosis Infection Detection Market by Application Outlook (USD Million)
5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033, for the following
5.5. Household Contacts With Pulmonary TB
5.5.1. Household Contacts With Pulmonary TB Market Revenue Estimates and Forecasts, 2021-2033 (USD Million)
5.5.2. Household Contacts With Pulmonary TB Market Revenue Estimates and Forecasts, 2021-2033 (Number of Tests, in Thousands)
5.6. PLHIV
5.6.1. PLHIV Market Revenue Estimates and Forecasts, 2021-2033 (USD Million)
5.6.2. PLHIV Market Revenue Estimates and Forecasts, 2021-2033 (Number of Tests, in Thousands)
5.7. Others
5.7.1. Others Market Revenue Estimates and Forecasts, 2021-2033 (USD Million)
5.7.2. Others Market Revenue Estimates and Forecasts, 2021-2033 (Number of Tests, in Thousands)
Chapter 6. U.S. Latent Tuberculosis Infection Detection Market: End Use Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. U.S. Latent Tuberculosis Infection Detection Market: End Use Movement Analysis
6.3. U.S. Latent Tuberculosis Infection Detection Market by End Use Outlook (USD Million)
6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033, for the following
6.5. Diagnostic Laboratories
6.5.1. Diagnostic Laboratories Market Revenue Estimates and Forecasts, 2021-2033 (USD Million)
6.5.2. Diagnostic Laboratories Market Revenue Estimates and Forecasts, 2021-2033 (Number of Tests, in Thousands)
6.6. Hospitals/Clinics
6.6.1. Hospitals/Clinics Market Revenue Estimates and Forecasts, 2021-2033 (USD Million)
6.6.2. Hospitals/Clinics Market Revenue Estimates and Forecasts, 2021-2033 (Number of Tests, in Thousands)
6.7. Academic & Research Institutions
6.7.1. Academic & Research Institutions Market Revenue Estimates and Forecasts, 2021-2033 (USD Million)
6.7.2. Academic & Research Institutions Market Revenue Estimates and Forecasts, 2021-2033 (Number of Tests, in Thousands)
Chapter 7. Competitive Landscape
7.1. Market Participant Categorization
7.2. Recent Developments & Impact Analysis by Key Market Participants
7.3. Company Market Share Analysis, 2025
7.4. Key Company Profiles
7.4.1. QIAGEN
7.4.1.1. Company overview
7.4.1.2. Financial performance
7.4.1.3. Product benchmarking
7.4.1.4. Strategic initiatives
7.4.2. Euroimmun US
7.4.2.1. Company overview
7.4.2.2. Financial performance
7.4.2.3. Product benchmarking
7.4.2.4. Strategic initiatives
7.4.3. bioMérieux
7.4.3.1. Company overview
7.4.3.2. Financial performance
7.4.3.3. Product benchmarking
7.4.3.4. Strategic initiatives
7.4.4. Oxford Immunotec
7.4.4.1. Company overview
7.4.4.2. Financial performance
7.4.4.3. Product benchmarking
7.4.4.4. Strategic initiatives
7.4.5. SD Biosensor, INC.
7.4.5.1. Company overview
7.4.5.2. Financial performance
7.4.5.3. Product benchmarking
7.4.5.4. Strategic initiatives
7.4.6. Quest Diagnostics
7.4.6.1. Company overview
7.4.6.2. Financial performance
7.4.6.3. Product benchmarking
7.4.6.4. Strategic initiatives
7.4.7. LabCorp
7.4.7.1. Company overview
7.4.7.2. Financial performance
7.4.7.3. Product benchmarking
7.4.7.4. Strategic initiatives
7.4.8. ARUP Laboratories
7.4.8.1. Company overview
7.4.8.2. Financial performance
7.4.8.3. Product benchmarking
7.4.8.4. Strategic initiatives
7.4.9. Mayo Clinic Laboratories
7.4.9.1. Company overview
7.4.9.2. Financial performance
7.4.9.3. Product benchmarking
7.4.9.4. Strategic initiatives
7.4.10. BioReference Laboratories
7.4.10.1. Company overview
7.4.10.2. Financial performance
7.4.10.3. Product benchmarking
7.4.10.4. Strategic initiatives
7.4.11. Par Pharmaceutical, Inc.
7.4.11.1. Company overview
7.4.11.2. Financial performance
7.4.11.3. Product benchmarking
7.4.11.4. Strategic initiatives
List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 List of all the CLIA labs in the U.S
Table 4 List of CLIA and NYS certified labs that perform QFT (CPT 86480), T-SPOT.TB (86481), TST (86580), and their volumes
Table 5 List of physicians and volumes ordered of the tests, split out by NPI, geography, and practice
Table 6 U.S. latent tuberculosis infection detection market, by test, 2021-2033 (USD Million)
Table 7 U.S. latent tuberculosis infection detection market, by application, 2021-2033 (USD Million)
Table 8 U.S. latent tuberculosis infection detection market, by end use, 2021-2033 (USD Million)
List of Figures
Figure 1 U.S. latent tuberculosis infection detection market segmentation
Figure 2 Market research process
Figure 3 Data triangulation techniques
Figure 4 Primary research pattern
Figure 5 Market research approaches
Figure 6 Value chain-based sizing & forecasting
Figure 7 QFD modelling for market share assessment
Figure 8 Market formulation & validation
Figure 9 U.S. latent tuberculosis infection detection market snapshot
Figure 10 Test snapshot
Figure 11 Application and end-use snapshot
Figure 12 Competitive landscape snapshot
Figure 13 Parent market outlook
Figure 14 Related/ancillary market outlook
Figure 15 Market dynamics
Figure 16 Market driver analysis (current & future impact)
Figure 17 Market restraint analysis (current & future impact)
Figure 18 Porter’s five forces analysis
Figure 19 SWOT analysis, by factor (political & legal, economic and technological)
Figure 20 U.S. latent tuberculosis infection detection market, test outlook key takeaways
Figure 21 U.S. latent tuberculosis infection detection market, test movement analysis
Figure 22 IGRA market revenue estimates and forecasts, 2021-2033 (USD Million)
Figure 23 IGRA market revenue estimates and forecasts, 2021-2033 (Number of Tests in Thousands)
Figure 24 Tuberculin Skin Test (TST) market revenue estimates and forecasts, 2021-2033 (USD Million)
Figure 25 Tuberculin Skin Test (TST) market revenue estimates and forecasts, 2021-2033 (Number of Tests in Thousands)
Figure 26 QFT market revenue estimates and forecasts, 2021-2033 (USD Million)
Figure 27 QFT market revenue estimates and forecasts, 2021-2033 (Number of Tests in Thousands)
Figure 28 T.SPOT market revenue estimates and forecasts, 2021-2033 (USD Million)
Figure 29 T.SPOT market revenue estimates and forecasts, 2021-2033 (Number of Tests in Thousands)
Figure 30 U.S. latent tuberculosis infection detection market, application outlook key takeaways
Figure 31 U.S. latent tuberculosis infection detection market, application movement analysis
Figure 32 Household Contacts with Pulmonary TB market revenue estimates and forecasts, 2021-2033 (USD Million)
Figure 33 Household Contacts with Pulmonary TB market revenue estimates and forecasts, 2021-2033 (Number of Tests in Thousands)
Figure 34 PLHIV market revenue estimates and forecasts, 2021-2033 (USD Million)
Figure 35 PLHIV market revenue estimates and forecasts, 2021-2033 (Number of Tests in Thousands)
Figure 36 Others market revenue estimates and forecasts, 2021-2033 (USD Million)
Figure 37 Others market revenue estimates and forecasts, 2021-2033 (Number of Tests in Thousands)
Figure 38 U.S. latent tuberculosis infection detection market, end use outlook key takeaways
Figure 39 U.S. latent tuberculosis infection detection market, end use movement analysis
Figure 40 Diagnostic Laboratories market revenue estimates and forecasts, 2021-2033 (USD Million)
Figure 41 Diagnostic Laboratories market revenue estimates and forecasts, 2021-2033 (Number of Tests in Thousands)
Figure 42 Hospitals/Clinics market revenue estimates and forecasts, 2021-2033 (USD Million)
Figure 43 Hospitals/Clinics market revenue estimates and forecasts, 2021-2033 (Number of Tests in Thousands)
Figure 44 Academic & Research Institutions market revenue estimates and forecasts, 2021-2033 (USD Million)
Figure 45 Academic & Research Institutions market revenue estimates and forecasts, 2021-2033 (Number of Tests in Thousands)
Figure 46 Key company categorization
Figure 47 Strategy mapping
